. 2021 Mar 1;17(5):285–296. doi: 10.1038/s41582-021-00467-y

Table 2.

Clinical features and outcome of GBS by region

Region	Country	Antecedent events (%)	Severity	Subtype (%)	Treatment (%)	Mortality (%)	Refs
*Worldwide*
Europe, America and parts of Asia	NA	Adults: 22–53 RTI, 6–26 gastroenteritis Children: 50–70 RTI, 7–14 gastroenteritis	Mean MRC-SS at entry 48-49; GBS-DS >2 at nadir 76%	NR	IVIg or PE 87–93	2–10	^{9,10,12,25,97}
Europe and North America	NA	NR	NR	90–95 AIDP, 5 axonal	NR	3–7	^10,48
*LMIC*
Middle East and North Africa	Egypt	24 RTI, 8 gastroenteritis	GBS-DS >2 at admission 76%	76 AIDP, 8 axonal	NR	16	⁴³
Middle East and North Africa	Morocco	51 RTI, 32 gastroenteritis	NR	81 AIDP, 19 axonal	NR		³⁶
South Asia	Bangladesh	18–19 RTI, 36–50 gastroenteritis	Mean MRC-SS at entry 22; GBS-DS >2 at nadir 93%	22–32 AIDP, 53–67 axonal	IVIg or PE 14, supportive care 86	14	^{12,14,22,96,109}
	India	35–65 RTI, 23–47 gastroenteritis	GBS-DS >2 at admission 76%	57–64 AIDP, 23–41 axonal	NR	4–12	^{41,57,106,113}
	Nepal	29 RTI, 3.2 gastroenteritis	NR	19 AIDP, 19 axonal	NR	6	¹³²
	Pakistan	35 RTI, 18 gastroenteritis	NR	46–63 AIDP, 31–34 axonal	NR	8	^42,56
Sub-Saharan Africa	Ethiopia	NR	NR	55 AIDP, 19 axonal	NR	25	⁴⁰
Sub-Saharan Africa	Tanzania	NR	NR	NR	NR	15	³⁸
*HIC*
East Asia and Pacific	China	24–63 RTI, 7–13 gastroenteritis	Mean GBS-DS at admission 2.57; GBS-DS at nadir 3.15; GBS-DS >2 at nadir 55%	34–57 AIDP, 22–29 axonal	NR	2–8	^52,59,99
	Taiwan	65 RTI, 4 gastroenteritis	NR	80 AIDP, 6% axonal	NR	2–5	^37,39
	Korea	11 RTI, 2 gastroenteritis	GBS-DS >2 at nadir 75%	NR	IVIg or PE 81, supportive care 19	2	¹³³
	Australia	NR	NR	54 AIDP, 4 axonal	NR	NR	¹²⁴
	Japan	NR	NR	34 AIDP, 45 axonal	IVIg or PE 90	NR	^49,122
Europe and Central Asia	Netherlands	41 RTI, 40 gastroenteritis	NR	60 AIDP, 4 axonal	IVIg or PE 91	2	^19,118
Europe and Central Asia	Spain	38 RTI, 27 gastroenteritis	GBS-DS >2 at admission 50%	83 AIDP, 8 axonal	IVIg or PE 86	2	^19,118
Latin America and the Caribbean	Brazil	56 RTI, 8 gastroenteritis	NR	82 AIDP, 18 axonal	NR	5	⁴⁴
Latin America and the Caribbean	Colombia	NR	Median MRC-SS at admission 40; median GBS-DS at nadir 4	78 AIDP, 2 axonal	NR	4	⁴

AIDP, acute inflammatory demyelinating polyneuropathy; GBS-DS, Guillain–Barré syndrome disability score; HIC, high-income countries; IVIg, intravenous immunoglobulin; LMIC, low-income and middle-income countries; NA, not applicable; NR, not reported; MRC-SS, Medical Research Council sum score; PE, plasma exchange, RTI, respiratory tract infection.